Peer-reviewed veterinary case report
Cannabidiol and chemotherapy effects on canine bladder cancer cells
By Inkol, Jordon M et al.·Published in PloS one·2021·Department of Clinical Studies, Canada·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Combination therapy with cannabidiol and chemotherapeutics in canine urothelial carcinoma cells.
- Species:
- dog
Plain-English summary
A study found that cannabidiol, a compound from cannabis, may help treat bladder cancer in dogs, specifically urothelial carcinoma, which is the most common type of bladder cancer in dogs. When tested in the lab, cannabidiol reduced cancer cell growth and increased cell death, especially when combined with certain chemotherapy drugs like mitoxantrone and vinblastine. However, it didn't work well with carboplatin, showing that not all combinations are effective. These findings suggest that cannabidiol could be a helpful addition to treatment plans for dogs with this type of cancer, but more research is needed to see how it works in real-life cases.
People also search for: dog bladder cancer treatment · cannabidiol for dog cancer · urothelial carcinoma in dogs · chemotherapy for dog bladder cancer
Abstract
BACKGROUND: Canine urothelial carcinoma is the most common form of canine bladder cancer. Treatment with chemotherapy has variable response rates leading to most dogs succumbing to their disease within a year. Cannabidiol is an emerging treatment within the field of oncology. In reported in vivo studies, cannabidiol has induced apoptosis, reduced cell migration, and acted as a chemotherapy sensitizer in various human tumor types. The aim of this study was to characterize the effects of cannabidiol on canine urothelial carcinoma cell viability and apoptosis as both a single agent and in combination with chemotherapy in vitro. RESULTS: Cannabidiol reduced cell viability and induced apoptosis in canine urothelial cells as determined by crystal violet viability assay and annexin V/propidium iodide flow cytometry. Furthermore, combinations of cannabidiol with mitoxantrone and vinblastine chemotherapy yielded significantly reduced cell viability and increased apoptosis compared to single agent treatment alone. The drug interactions were deemed synergistic based on combination index calculations. Conversely, the combination of cannabidiol and carboplatin did not result in decreased cell viability and increased apoptosis compared to single agent treatment. Combination index calculations suggested an antagonistic interaction between these drugs. Finally, the combination of the non-steroidal anti-inflammatory drug piroxicam with cannabidiol did not significantly affect cell viability, although, some cell lines demonstrated decreased cell viability when mitoxantrone was combined with piroxicam. CONCLUSIONS: Cannabidiol showed promising results as a single agent or in combination with mitoxantrone and vinblastine for treatment of canine urothelial carcinoma cells. Further studies are justified to investigate whether these results are translatable in vivo.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/34352013/